We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
UK-based Achilles Therapeutics has announced the closing of its £100m Series B financing round, which was led by new investor RA Capital Management and founding investor Syncona.
Swiss drugmaker Roche’s push into personalised cancer medicines hit a milestone with Japanese approval of a new drug, Rozlytrek, that targets patients who must be identified via genetic profiling.